Only 20% of lung cancer cases caught by x-rays
the ONA take:
According to a Norwegian study, ultralow-dose computerized tomography (CT) scans catch 89% of lung cancer cases, while x-ray examinations only catch 18% of cases. In the study, researchers asked radiologists at Oslo University Hospital in Oslo, Norway, to examine x-ray and CT scan images and to identify possible diseases in the chest.
In Norway, over 1 million people undergo x-ray imaging and most patients with lung cancer are first diagnosed by using x-ray examinations. Despite the increased accuracy with CT imaging, clinicians have been hesitant to use this method as first-line screening because of the increased radiation. Until modern ultralow-dose CT imaging, the radiation dose has been 100 times greater than x-ray imaging or equal to 5 years of natural background radiation.
If an examination with x-ray is negative, substantial time may pass before a patient is recommended for CT imaging. That time may be enough for the lung cancer to grow, spread, and become deadly. According to the Centers for Disease Control and Prevention, lung cancer is deadlier than any other type of cancer for both males and females in the United States. Unfortunately, CT scans are substantially more expensive than x-ray examinations.
With modern ultralow-dose CT, the radiologists hit the bull's eye on lung cancer 90% of the time.
Each year, 2800 Norwegians develop the dreaded disease. Their prognosis is unpromising: six out of seven die within five years. What is especially unfortunate about lung cancer is that the tumour has ample space to grow.
It can thus grow for a long time before being detected. Most patients have their first diagnosis made by x-ray imaging. Each year, Oslo University Hospital takes 30 000 chest x-rays. Nationwide, this number exceeds one million.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|